Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Conflicted on These Healthcare Names: Bausch Health Companies (BHC), Thermo Fisher (TMO) and Mineralys Therapeutics, Inc. (MLYS)

Tipranks - Tipranks - Fri Oct 31, 2025

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bausch Health Companies (BHC – Research Report), Thermo Fisher (TMO – Research Report) and Mineralys Therapeutics, Inc. (MLYS – Research Report).

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Bausch Health Companies (BHC)

In a report released today, Douglas Miehm from RBC Capital maintained a Hold rating on Bausch Health Companies, with a price target of $10.00. The company’s shares closed last Wednesday at $5.90.

According to TipRanks.com, Miehm is a 3-star analyst with an average return of 3.6% and a 48.1% success rate. Miehm covers the Healthcare sector, focusing on stocks such as Bausch + Lomb Corporation, Aurinia Pharmaceuticals, and Pacira Pharmaceuticals. ;'>

Currently, the analyst consensus on Bausch Health Companies is a Hold with an average price target of $8.33, implying a 34.6% upside from current levels. In a report issued on October 24, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a C$9.00 price target.

See the top stocks recommended by analysts >>

Thermo Fisher (TMO)

In a report released today, Luke Sergott from Barclays maintained a Buy rating on Thermo Fisher, with a price target of $625.00. The company’s shares closed last Wednesday at $558.31.

According to TipRanks.com, Sergott has 0 stars on 0-5 stars ranking scale with an average return of -6.2% and a 41.0% success rate. Sergott covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Fortrea Holdings Inc., and Pacific Biosciences. ;'>

Currently, the analyst consensus on Thermo Fisher is a Strong Buy with an average price target of $615.44, implying a 10.2% upside from current levels. In a report issued on October 22, William Blair also maintained a Buy rating on the stock.

Mineralys Therapeutics, Inc. (MLYS)

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating on Mineralys Therapeutics, Inc. today and set a price target of $52.00. The company’s shares closed last Wednesday at $40.14.

According to TipRanks.com, Caufield is a 5-star analyst with an average return of 16.7% and a 49.5% success rate. Caufield covers the Healthcare sector, focusing on stocks such as 4D Molecular Therapeutics, Phathom Pharmaceuticals, and Adverum Biotechnologies. ;'>

Currently, the analyst consensus on Mineralys Therapeutics, Inc. is a Strong Buy with an average price target of $44.57.

Read More on BHC:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).